Dr. Che-Kai Tsao, MD

Dr. Tsao practices at Schlanger, Gottlieb Partners Council Breast Imaging Center in Lake Success, New York.

Dr. Tsao's NPI, 1588823744, was assigned on June 3, 2008. Dr. Tsao graduated from State University of New York Downstate Medical Center College of Medicine in 2005. Dr. Tsao holds New York license 248872.

Dr. Tsao's primary practice is Schlanger, Gottlieb Partners Council Breast Imaging Center, at 450 Lakeville Rd, Lake Success, NY 11042. The practice phone is (516) 734-8281.

Dr. Tsao's primary practice is Schlanger, Gottlieb Partners Council Breast Imaging Center in Lake Success, New York. Dr. Tsao is also affiliated with Long Island Jewish Medical Center. The medical group on file is Mount Sinai Institute for Liver Medicine. Dmand AI also links Dr. Tsao to 2 more hospitals, 2 group practices and clinics, 1 clinical lab and 1 medical group, each named with a free account. Dr. Tsao's employer is on file too: a breast imaging center.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Tsao practices, 7 sites in all. Vendor and product names are available with a free account.

Medical oncology is Dr. Tsao's primary specialty in the NPI Registry, under taxonomy code 207RX0202X. Dr. Tsao is licensed in New York.

Dmand AI lists breast cancer, colorectal cancer, lung cancer and prostate cancer among the conditions Dr. Tsao treats.

CMS data shows 457 Medicare services from Dr. Tsao across 5 procedure codes in 2024, for 160 Medicare patients. Medicare paid $44,976 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 160 Medicare patients who saw Dr. Tsao in 2024. The largest group is 65 to 74, with 70 patients. 75% of them have cancer, and 75% have high blood pressure. 21% are also on Medicaid. Their average risk score is 2.50, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Tsao's median patient age at 73, with 8% women.

In 2024, Dr. Tsao wrote 907 Medicare Part D claims for 140 patients. 42% of them were for generic drugs. CMS names the drug for 716 of them, across 16 drugs with 11 or more claims each, at $4,577,834 in total drug cost. In 2023, CMS named 667 claims across 16 drugs.

Dr. Tsao accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Tsao as offering telehealth.

Dmand AI links 57 papers to Dr. Tsao, published from 2010 to 2025. 2021 was the busiest year, with 10. The most frequent topics are Prostatic Neoplasms, Castration-Resistant, Prostatic Neoplasms and Kidney Neoplasms. Dr. Tsao has published most often in Clin Genitourin Cancer. Dr. Tsao's most frequent co-authors are Matthew D. Galsky, MD, William K. Oh, MD and William Oh, MD.

Dmand AI links Dr. Tsao to 2 clinical trials. 1 is still active or recruiting. Conditions studied include Carcinoma, Renal Cell, Prostatic Neoplasms and Kidney Neoplasms. Open Payments lists research payments to Dr. Tsao that name 4 trials.

CMS Open Payments shows 123 general payments to Dr. Tsao from 17 drug and device companies from 2016 to 2025. Consulting fees make up the largest share, 64% of the total. Pfizer Inc. paid the most, $37,136. It also lists 11 research payments totaling $7,666 from 2016 to 2025, naming 4 clinical trials.

Dmand AI lists 7 awards for Dr. Tsao, most recently Solid Tumor Faculty Teacher of the Year in 2023.

Dr. Tsao graduated from State University of New York Downstate Medical Center College of Medicine in 2005.

Dr. Tsao is in network with 18 carriers, including Aetna, Blue Cross Blue Shield of Michigan and Elevance. PPO plans come from the most carriers, 11. Check the plan with the practice before a visit.